Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-02-12 Share Issue/Capital Cha…
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a press release announcing the issuance of new common shares to settle debt and interest obligations under debentures. This is an announcement of a share issue/capital change rather than an earnings release, management discussion, or general regulatory notice. Therefore it best fits the “Share Issue/Capital Change” category (SHA).
2025-02-12 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release reporting Q3 2024 financial performance highlights—revenues, gross profit, adjusted EBITDA—and includes CEO commentary and key metrics. It is the initial announcement of quarterly results rather than a full interim report, fitting the definition of an Earnings Release (ER). Q3 2024
2024-12-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 87% confidence The document is a NI 52-109 form (Form 52-109FV2) certification by the CFO of interim filings (interim financial report and interim MD&A) for the period ended September 30, 2024. This is not the interim report itself (IR), nor an MD&A, nor any announcement of dividend, financing, or management changes. It is a regulatory compliance certificate required under Canadian securities rules, serving as a regulatory filing. It does not present financial data or an audit opinion per se, and it does not fit into any other specialized category. Therefore, it is classified under the fallback category for general regulatory filings (RNS).
2024-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 92% confidence The document is Form 52-109FV2, a regulatory certification (Venture Issuer Basic Certificate) for interim filings under Canadian NI 52-109. It is not the interim financial report or MD&A themselves, but a required regulatory certification form. It does not announce publication of a report but constitutes a standalone regulatory filing. This does not fit specific categories like interim report, earnings release, or governance report. It falls into the fallback category for general regulatory filings.
2024-11-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three and nine months ended September 30, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Deficit, and Statement of Cash Flows) along with detailed notes to the financial statements. It is a formal quarterly financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-29 English
Interim MD&A - English.pdf
Management Reports Classification · 92% confidence The document is titled “Management’s Discussion and Analysis For the three and nine months ended September 30, 2024.” It contains management’s narrative on financial condition, operating performance, risks, and outlook for the interim period and refers to unaudited interim consolidated financial statements. This corresponds exactly to the Management Reports (MD&A) category under code MDA.
2024-11-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.